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Lack of varied endometrial expression 
of proprotein convertase 6 in infertile women
with minimal grade endometriosis 
and idiopathic infertility
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Abstract 
Objective: Proprotein convertase 6(PC6) is known to be the key enzyme involved in the transformation of many
hormones, cytokines and their receptors into their active forms. Experimental in vitro studies have also proven that
lack of PC6 in the endometrium prevents decidualisation. Therefore in our study we have aimed at determining
whether infertility in some patients might be attributable to decreased expression of PC6. 
Material and methods: With the use of RealTime PCR we have studied the expression level of PC6 in receptive
phase endometria from 36 idiopathic infertile patients, 26 infertile patients with minimal grade endometriosis and
compared those results with fertile, age-matched controls. The endometria were collected 7-9 days after ovulation. 
Results: There were no statistically significant differences regarding the expression of PC6 in endometria from
patients with idiopathic infertility, infertile patients with endometriosis and controls.
Conclusions: Since there is no detectable difference in PC6 expression, the decreased expression of PC6 is unlike-
ly to cause infertility. 
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Streszczenie 
Cel pracy: Konwertaza proproteinowa 6 (PC6) jest kluczowym enzymem bioràcym udzia∏ w przekszta∏ceniu wielu
prohormonów, cytokin i ich receptorów w aktywne formy. Badania eksperymentalne in vitro dowiod∏y, i˝ brak PC6
uniemo˝liwia przemian´ doczesnowà w endometrium. Naszym celem by∏a ocena czy u pacjentek niep∏odnych czyn-
nikiem wywo∏ujàcym niep∏odnoÊç mo˝e byç zaburzona ekspresja PC6.
Materia∏ i metoda: Stosujàc RT-PCR zbadaliÊmy poziom ekspresji PC6 w fazie receptywnej endometrium u 36 ko-
biet z niep∏odnoÊcià idiopatycznà, 26 pacjentek z endometriozà minimalnà oraz porównaliÊmy te wyniki z p∏odny-
mi pacjentkami dobranymi pod wzgl´dem wieku. Endometrium zosta∏o pobrane 7-9 dni po owulacji.
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Introduction
Idiopathic infertility and infertility associated with mini-
mal grade endometriosis present physicians with a diagnostic,
as well as therapeutic dilemma [1]. Idiopathic infertility occurs
in about 15% of patients suffering from infertility, while dif-
ferent stages of endometriosis affect about 30% of them [2, 3].
Since the cause of idiopathic infertility remains unknown,
the treatment tends to be empirical at best, including ovarian
stimulation, intrauterine inseminations, and finally assisted
reproductive techniques [4]. In case of patients with minimal
endometriosis there have been numerous possible causes of
the accompanying infertility, including immunologic imbal-
ances, hormonal changes and anomalies within the eutopic
endometrium [5, 6]. Therefore, the treatment choices are simi-
lar to those of idiopathic infertility and include in-vitro fertil-
ization-embryo transfer (IVF-ET) cycles, though in patients
with minimal endometriosis the results of IVF cycles are
invariably poorer than those with e.g. male factor infertility
[7]. The success of IVF cycles depends on a whole range of
factors, mainly the ovum and embryo quality atraumatic
transfer of an embryo and finally, the receptivity of the
endometrium [7, 8, 9]. While there are ways to assess the qual-
ity of the oocytes and the embryo, including pre-implantation
genetic diagnostics, the implantation rate remains quite low
[10]. 
Thus, there exists an obvious need to study the endometri-
al receptiveness. Routine histological assessment is no longer
recommended as part of diagnostic tests for infertility [11].
Attention has been drawn to molecular and genetic aspects of
endometrial receptivity [12]. One study, aimed at finding new
endometrial targets for contraception, concluded that among
many enzymes present in the human endometrium there is one
that seems to be indispensable for a proper decidualisation of
stromal cells [13], namely proprotein convertase 6 (PC6). It is
a serine protease that is structurally related to bacterial subtil-
isins [14]. Their function is the conversion of various inactive
peptide hormones, enzymes and growth factors into their
active forms [15]. Since PC6 acts directly within the
endometrium, it regulates the timely and orderly conversion of
many substances, a process which is critical for organized
events that occur during the creation of window of implanta-
tion [16]. There are two forms of PC6 in mice: membrane-
bound and soluble, while in humans the presence of only the
soluble form has been confirmed [17, 18]. Researchers found
that in mice PC6 is up-regulated at the time of the embryo
implantation primarily in cells surrounding the embryo [19]. 
Blocking of PC6 production by antisense oligonucleotides
resulted in total inhibition of the implantation [16]. In human
endometrium PC6 is present throughout the cycle, with
increased expression during the midsecretory phase [13]. Sim-
ilarly, in humans the blocking of PC6 activity stops the decid-
ualisation process, thus preventing the preparation of the
endometrium for the embryo attachment [20, 21]. These stud-
ies are also supported by work from Kao et al. who have
shown an increase in the expression of PC6 around the time of
implantation, revealing its vital role in human reproduction
[12]. That is why we have decided to check whether patients
with both idiopathic infertility and minimal endometriosis
associated infertility exhibit local, i.e. endometrial, decreased
PC6 expression which might explain the cause of infertility in
those patients and, if so, how much decreased expression of
PC6 might be attributed to infertility. 
Materials and methods
The study was conducted in the Division of Reproduction,
Department of Obstetrics, Gynecology and Gynecological
Oncology  of K. Marcinkowski Medical University in Poznan,
Poland, between January 2006 and February 2007. Only infer-
tile patients with all diagnostic tests negative or those patients
who had minimal endometriosis were included in the study.
Each couple underwent the following tests: semen analysis,
ovulation tracking, hysterosalpingography, hormonal studies
and laparoscopy with hysteroscopy. We had 36 patients with
idiopathic infertility and 26 infertile patients with minimal
grade endometriosis diagnosed by means of laparoscopy and
histology, following the American Fertility Society recom-
mendations [22]. The mean duration of infertility in both
groups was 3.4 years (1-5 years) and 3.2 years (1.2-6 years),
respectively. Furthermore, 24 patients from the same age
group, with at least one child, without miscarriages and with
negative history of infertility and endometriosis were enrolled
in the study. Those patients were admitted to the hospital due
to non-endometrial diseases, and were asked to donate
endometrium for the purpose of the research. The study pro-
tocol was approved by the local ethical committee and the
patients signed informed consent forms. None of the patients
in all groups, including the controls, had taken any hormonal
preparations for at least three months prior to the study.
Collection of samples and RNA isolation
All patients had a biopsy sample obtained 7-9 days after
ovulation, confirmed by ultrasound follicular tracking. The
endometrial sample was placed in RNAlaterTM buffer from
Qiagen (Hilden, Germany) and frozen until extraction. 
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Wyniki: Nie stwierdziliÊmy statystycznie znamiennych ró˝nic w ekspresji PC6 w endometrium z grupy z niep∏odno-
Êcià idiopatycznà, niep∏odnymi pacjentkami z endometriozà a grupà kontrolnà. 
Wnioski: Wydaje si´, ˝e zaburzona ekspresja PC6 nie jest przyczynà niep∏odnoÊci.
S∏owa kluczowe: niep∏odnoÊç / endometrioza / konwertaza proproteinowa /
/ endometrium /
The isolation of total RNA was done with the use of
RNAeasy Mini Kit (Qiagen, Germany). QiaShredder
columns were used for homogenization (Qiagen) following the
manufacturers instructions. The total mRNA was treated with
QantiTect Reverse Transcription (Qiagen) to acquire cDNA. 
Primers design and qPCR reaction
RNA specific primers for RealTime PCR were created
with the Primer3 software (http://frodo.wi.mit.edu/primer3)
based on mRNA (NM_006200) sequence from NCBI Gene
database (http://www.ncbi.nlm.nih.gov/). The thermodynamic
features of the designed primers were analyzed with the use of
OligoAnalyzer1.2 software first, followed by the specificity of
constructed primer check against BLAST database
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The obtained results
confirmed the specificity of the designed primers for the
human PC6 gene transcript: GAPDH - forward:
ACAGTCAGCCGCATCTTCTT and reverse:
ACGACCAAATCCGTTGACTC and for PC6 - forward:
TGCAGTGACAATACACATCC and reverse:
TCTCTCAATTCCGTCATCC.  
The resulting DNA was checked on agarose gel for the
confirmation of the set primers specificity and additionally,
secondly derivative analysis melting curve product of these
primers set Real Time PCR reaction was used to confirm the
specificity. 
The resulting cDNA samples were used as matrix for
RealTime PCR which was conducted in duplicate, on
RotorGene 3000 RealTime thermocycler (Corbett Research).
The optimized protocol was used with the mastermix includ-
ing HotStart polymerase (DyNAmo HS SYBRGreen qPCR
Kit from Finnzymes, Espoo, Finland). Thermal profile was
95°C for 15min; 94°C for 10 sec; 55°C for 25 sec; 72°C for 30
sec and at 79°C first data acquisition. The thermocycler was
set for 40 runs. After all runs completed, 72°C for 10min cycle
was accomplished and next the melting curve was established
by changing the temperature from 72°C to 95°C, increasing by
0,5°C with each step, which in turn allowed for calculation of
the second derivative to confirm uniformity of the resultant
products of amplification. The expression of PC 6 was com-
pared to a reference gene that is glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), whose expression in cells is univer-
sally considered to be constant throughout the whole men-
strual cycle. 
In order to determine the efficiency of the qPCR reaction
for both investigated transcripts, 10 subsequent dilutions of
the linear DNA molecule were used. Triplicate qPCR reaction
was performed for each dilution. On the basis of the results
the thermocycler PCR analysis software automatically deter-
mined the efficiency of both reactions and constructed the
standard curve which, in turn, was used to determine the tran-
script level in the tests. They were analyzed in duplicate to cor-
rect the standard curve.
The transcription level of PC6 was shown in relation to the
GAPDH and calculated using REST®2005 analyzing soft-
ware v.1.9.9 from Corbett Research, which also automatically
calculates the differences between studied groups. The mean
GAPDH expression levels did not differ significantly among
the groups.
Results
There was no difference in the expression of PC6 between
all infertile patients (idiopathic infertility and endometriosis)
and controls. The results are presented in Table I.
There was also no statistically significant difference in PC6
expression in endometria from patients with idiopathic infer-
tility and controls, minimal endometriosis and controls. The
results are presented in Tables II and III.
Furthermore, there was no difference between the expres-
sion of PC6 in patients with idiopathic infertility vs. minimal
endometriosis. (Table IV). 
Discussion
To the best of our knowledge this is the first study in the
literature comparing the in vivo expression of PC  6 in fertile
and infertile patients. Infertile patients require advanced diag-
nostic and therapeutic methods to improve their chances for
pregnancy. 
In natural cycles the monthly fecundability remains at the
level of 30% [23]. We know that a large number of these early
loses might be attributed to embryo defects [10]. However, one
needs to bear in mind that even with the use of Preimplanta-
tion Genetic Screening which effectively rejects abnormal
embryos, the implantation rate still remains low [10]. 
Part of the blame for such poor results might be attributed
to the faulty implantation caused by poor endometrial recep-
tivity at the time of embryo transfer [9]. Any disturbances in
the window of implantation might lead to the rejection of the
normal embryo and result in infertility. In our paper we have
chosen to assess the role of PC6 as the potential cause of infer-
tility. The choice was based on two major facts. Firstly, that
PC6 is involved in the transformation of many substances into
their active form. Many enzymes, cytokines, growth factors
and hormones are dependant on the proper expression and
function of PC6 [15]. Potentially, many of the factors taking
part in the creation and maintenance of receptivity period of
the endometrium might be influenced by aberrant expression
of PC 6. Secondly, that it has been proven in a mouse that
inhibiting the expression of PC6 leads invariably to a complete
block of implantation [16]. Patients with idiopathic infertility
and those with minimal grade endometriosis may have, as yet
undiscovered, defects within the eutopic endometrium that
lead to implantation failures. Therefore, in our present study
we decided to assess the expression profiles of PC6 in those
two subgroups of patients to determine whether it might be
due to infertility. 
In our current study we were unable to demonstrate any
differences between the expression level for PC6 between
patients with idiopathic infertility, minimal grade endometrio-
sis and fertile population. Based on our research we came to
the conclusion that infertility caused by decreased expression
of PC6 is quite an uncommon phenomenon for several rea-
sons. Conclusively, PC6 is a very important enzyme in
humans. It regulates many biological pathways, including
those in the gastrointestinal tract, aorta, kidneys, lungs and
many others; therefore, lack of PC6 might be incompatible
with life [16], though a local (endometrial) decrease in the
expression might be expected. 
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Table I. The reaction efficiencies, expression results in endometria and statistical evaluation of proprotein convertase 6 (PC6) 
differences between the entire infertile group and controls.
Table II. The reaction efficiencies, expression results in endometria and statistical evaluation of proprotein convertase 6 (PC6) 
differences between idiopathic infertility and controls groups.
Table III. The reaction efficiencies, expression results in endometria and statistical evaluation of proprotein convertase 6 (PC6) 
differences between infertile patients with minimal endometriosis and controls.
Table IV. The reaction efficiencies, expression results in endometria and statistical evaluation of proprotein convertase 6 (PC6) 
differences between patients with idiopathic infertility and minimal endometriosis group..
Until now there is no gene deletion model for PC6 in a
mouse, which seems to confirm our earlier hypothesis. Since
mouse and human PC6 proteins have 95% homology, it indi-
cates that this gene is highly conserved across species [16]. This
might explain the lack of difference in the expression between
control and study groups in our research. Also, since the only
form that has been identified in humans is soluble, it is possi-
ble to speculate that total effects exerted by this enzyme might
be correlated with posttranslational processes. 
Conclusion
Since PC6 is involved in the activation of many molecules
associated with either initial embryo attachment (like inte-
grins) or the preparation of the endometrium for the embryo
invasion (like epidermal growth factor and vascular endothe-
lial growth factor), it would be worthwhile to look for possible
substrates that could affect the local expression of PC6 within
the endometrial cavity [15, 23, 24]. However, studies have
demonstrated that PC6 expression, despite being more promi-
nent in the second half of the cycle, so called ‘progesterone
dependant’, does not increase with neither estrogens nor prog-
esterone stimulation [19].
The endometrium has a natural state of receptiveness [12].
In vivo studies will help determine which of the genes that are
up- or down-regulated in the implantation window are truly
the cause of infertility and which are redundant in this
process. Therefore, a functional study of PC6 action in the
endometrial fluid might explain whether infertility could be
caused by altered PC6 function. 
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